Drug intelligence / Profile preview

HS-101

Development stage: Unknown
Lead developer: HaplnScience
Modality: Recombinant Proteins and Enzymes
Administration: Intraarticular

Overview

HS-101 is a recombinant protein biologic based on the endogenous protein HAPLN1 (Hyaluronan and proteoglycan link protein 1), developed by HaplnScience for the treatment of osteoarthritis. The drug functions by modulating the Smad2/3 signaling pathway and interacting with the extracellular matrix (ECM) to promote tissue regeneration and maintain joint integrity. By addressing the underlying degenerative processes in the joint, HS-101 aims to provide a disease-modifying effect for patients with osteoarthritis. It is currently in Phase 1 clinical development.

Other names: HAPLN1HAPLN-1HAPLN 1Hyaluronan and proteoglycan link protein 1

Targets

Hyaluronan–aggrecan extracellular matrix complexTransforming growth factor beta receptor type 1 (TGFβR1)–SMAD2/3 signaling axisSMAD2 (Mothers against decapentaplegic homolog 2)

Beyond the preview

Go deeper on HS-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HS-101.